BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio
BioMarin Pharmaceutical is set to deepen its push into rare metabolic diseases after announcing a definitive agreement to acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion. The deal would add two marketed therapies—Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease—while also bringing in a Phase 3 kidney-disease program that could widen BioMarin’s late‑stage pipeline. BioMarin Corporate+1 The acquisition is the latest example of a larger biotech company using M&A to secure near‑term revenue and strengthen long‑term growth, particularly in rare disease categories where commercialization requires specialized manufacturing, reimbursement know‑how, and tight engagement with
